Get started
EEE

EGETIS THERAPEUTICS AB

No trades
See on Supercharts
Overview
Financials News Discussions Technicals Forecast Seasonals

EGTX chart


Full chart

EGTX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.71 B‬ SEK
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.095 SEK
Net income (FY)
‪−326.90 M‬ SEK
Revenue (FY)
‪57.60 M‬ SEK
Shares float
‪194.07 M‬
Beta (1Y)
0.34

Employees


Employees (FY)
28
Change (1Y)
+11 +64.71%
Revenue / Employee (1Y)
‪203.04 K‬ SEK
Net income / Employee (1Y)
‪−1.15 M‬ SEK

About EGETIS THERAPEUTICS AB


Sector
Health Technology
CEO
Nicklas Westerholm
Headquarters
Stockholm
Website
egetis.com
Founded
2006
ISIN
SE0003815604
FIGI
BBG001K77XP2
Egetis Therapeutics AB is an innovative and integrated pharmaceutical company, which engages in the development of new drugs for treatment of serious diseases. Its projects include Emcitate for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency. The company was founded by Torsten Almén, Heidi Brurok, Louis J. Ignarro, Per Jynge, Jan Olof Gustav Karlsson, Ingemar Lundström, and Rob Towart in 2006 and is headquartered in Stockholm, Sweden.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

EGTX news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of EGTX is 4.750 SEK — it has increased by 10.08% in the past 24 hours. Watch EGETIS THERAPEUTICS AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange EGETIS THERAPEUTICS AB stocks are traded under the ticker EGTX.
EGTX stock has risen by 7.95% compared to the previous week, the month change is a 7.47% rise, over the last year EGETIS THERAPEUTICS AB has showed a −3.26% decrease.
We've gathered analysts' opinions on EGETIS THERAPEUTICS AB future price: according to them, EGTX price has a max estimate of 16.60 SEK and a min estimate of 11.00 SEK. Watch EGTX chart and read a more detailed EGETIS THERAPEUTICS AB stock forecast: see what analysts think of EGETIS THERAPEUTICS AB and suggest that you do with its stocks.
EGTX reached its all-time high on Jun 10, 2024 with the price of 9.300 SEK, and its all-time low was 3.005 SEK and was reached on Jun 15, 2022. View more price dynamics on EGTX chart.
See other stocks reaching their highest and lowest prices.
EGTX stock is 18.72% volatile and has beta coefficient of 0.34. Track EGETIS THERAPEUTICS AB stock price on the chart and check out the list of the most volatile stocks — is EGETIS THERAPEUTICS AB there?
Today EGETIS THERAPEUTICS AB has the market capitalization of ‪1.71 B‬, it has increased by 9.98% over the last week.
Yes, you can track EGETIS THERAPEUTICS AB financials in yearly and quarterly reports right on TradingView.
EGETIS THERAPEUTICS AB is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
EGTX earnings for the last quarter are −0.28 SEK per share, whereas the estimation was −0.30 SEK resulting in a 8.24% surprise. The estimated earnings for the next quarter are −0.34 SEK per share. See more details about EGETIS THERAPEUTICS AB earnings.
EGETIS THERAPEUTICS AB revenue for the last quarter amounts to ‪17.00 M‬ SEK, despite the estimated figure of ‪15.65 M‬ SEK. In the next quarter, revenue is expected to reach ‪16.85 M‬ SEK.
EGTX net income for the last quarter is ‪−86.20 M‬ SEK, while the quarter before that showed ‪−71.90 M‬ SEK of net income which accounts for −19.89% change. Track more EGETIS THERAPEUTICS AB financial stats to get the full picture.
No, EGTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 28.00 employees. See our rating of the largest employees — is EGETIS THERAPEUTICS AB on this list?
Like other stocks, EGTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EGETIS THERAPEUTICS AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EGETIS THERAPEUTICS AB technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EGETIS THERAPEUTICS AB stock shows the sell signal. See more of EGETIS THERAPEUTICS AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.